MangoRx’s $99 TRT Program Drives 336% Sales Surge, Cuts CAC by 54%
MangoRx’s $99/month injectable TRT program achieved 336% month-over-month sales growth and reduced customer acquisition costs by 54% since its mid-December launch. The company aims to make TRT its primary growth driver while expanding its telehealth platform to offer broader men’s health solutions.
1. Product Launch and Performance
MangoRx launched its all-inclusive injectable TRT program at $99 per month in mid-December, combining doctor visits, lab work and medication. Since launch, the program has delivered 336% month-over-month sales growth while cutting customer acquisition costs by 54%.
2. Market Opportunity and Growth Strategy
The global testosterone replacement therapy market is valued at approximately $2.11–$2.2 billion in 2025 and is projected to grow at a 3.9% CAGR. MangoRx expects its TRT offering to become the company’s primary growth engine, leveraging its efficient telehealth platform to capture market share in this high-demand segment.
3. Platform Expansion and Future Plans
Beyond injectable TRT, MangoRx plans to introduce oral formulations like PRIME by MangoRx powered by Kyzatrex® and expand into additional men’s health treatments. The company is investing in telemedicine enhancements, patient safety protocols and regulatory compliance to support a broader suite of wellness solutions.